	US 11,718,834 B2
	Compositions and methods for producing recombinant AAV
Andrea J. Kang, Richmond, CA (US); Richard T. Surosky, Richmond, CA (US); and Alex Michael Ward, Richmond, CA (US)
Assigned to Sangamo Therapeutics, Inc., Brisbane, CA (US)
Filed by Sangamo Therapeutics, Inc., Richmond, CA (US)
Filed on Feb. 14, 2020, as Appl. No. 16/790,841.
Claims priority of provisional application 62/806,317, filed on Feb. 15, 2019.
Prior Publication US 2020/0283739 A1, Sep. 10, 2020
Int. Cl. C12N 15/86 (2006.01); C12N 15/864 (2006.01); A61K 35/761 (2015.01); C12N 7/00 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 35/761 (2013.01); C12N 15/86 (2013.01); C12N 15/864 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14132 (2013.01); C12N 2750/14143 (2013.01)]

16 Claims

1. A nucleic acid construct comprising a nucleotide sequence encoding adeno-associated virus (AAV) VP1, VP2, and VP3 proteins, wherein the VP1 protein and the VP2 protein comprise two or more mutations selected from a first group consisting of S157A, T162S, Q164A, S179T, L188I, T194A, A196S, A197G, P200S, and T201L, (numbering according to SEQ ID NO:1) relative to wildtype VP1 and VP2 proteins.